EDA and neoplasm: The final formulation (Figure 4a), dubbed Eda‐I1‐HlpA, was designed to target the surface of CRC cells (Figure 4bi), convert dietary glucosinolate to sulforaphane (a cancer inhibitor) at the CRC‐site (Figure 4bii), and be released from the CRC‐site following tumor eradication (Figure 4biii).